INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
This Compritol® 888 ATO, a versatile lipid ingredient extensively employed in pharmaceuticals and cosmeceuticals, holds considerable promise for topical drug delivery systems targeting conditions such as myelomalacia. This review investigates the manifold applications of Compritol 888 ATO, ranging from its role as a lubricant and coating agent in oral solid medications to its integration into lipid-based colloidal drug delivery platforms like solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). Myelomalacia, a condition where the softening of the spine poses an increased risk to nerves, particularly from bulging discs and similar ailments, can occur across any segment of the spine, although it is most prevalent in the neck and lower back areas. Effective therapy necessitates the efficient penetration or permeation of active molecules through the skin. Nano-sized drug carrier systems offer several key advantages crucial for this purpose. They enhance drug penetration into the skin, thereby reducing undesirable side effects. Additionally, these systems enable site-specific targeting of molecules within the skin, enhance formulation stability, and facilitate controlled release of drugs. By leveraging these advantages, nano-sized drug carrier systems hold significant promise for advancing therapies aimed at managing conditions like myelomalacia. Despite the proven effectiveness of Compritol® 888 ATO in prolonging drug release and enhancing formulation stability, gaps persist in understanding its chemical composition, long-term viability, and interactions with gastrointestinal enzymes. Addressing these knowledge deficiencies is crucial for developing reliable and safe drug delivery systems utilizing Compritol 888 ATO, thus advancing therapeutic interventions for conditions like myelomalacia. Utilizing NSAIDs hydrogel with Compritol 888 ATO for myelomalacia management offers localized drug delivery, enhanced penetration, sustained release, reduced side effects, improved compliance, minimized interactions, and potential synergistic effects.
"COMPRITOL 888 ATO HYDROGEL: A PROMISING TOPICAL DRUG DELIVERY SYSTEM FOR MYELOMALACIA ", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 2, page no.d293-d303, February-2024, Available :http://www.ijnrd.org/papers/IJNRD2402331.pdf
Downloads:
000118777
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn